Daiichi Sankyo Terminates Development and Commercialization Agreement with Charleston Laboratories Regarding Hydrocodone Products in the U.S., including CL-108

By JPN, Pharmaceutical

Daiichi Sankyo Terminates Development and Commercialization Agreement with Charleston Laboratories Regarding Hydrocodone Products in the U.S., including CL-108

Tokyo, Japan and Basking Ridge, NJ (August 31, 2017) — Daiichi Sankyo Co., Ltd. (TSE: 4568), and its U.S. subsidiary, Daiichi Sankyo, Inc. announced today that the company has elected to terminate its 2014 development and commercialization agreement with Charleston Laboratories, forgoing further involvement with the development and commercialization of Charleston Laboratories’ hydrocodone and will be returning all of its rights to those products to Charleston Laboratories Media & Investors – Daiichi Sankyo

http://www.daiichisankyo.com/media_investors/media_relations/press_releases/detail/006704.html

More from tokioX :

  1. Daiichi Sankyo: Applying for Approval of mRNA Vaccine！
  2. COVID-19: AstraZeneca supplies corona vaccine to Japan: Daiichi Sankyo, Meiji Seika Pharma
  3. 💊Daiichi Sankyo, Inc. Aligns U.S. Commercial Operations to Current Portfolio and Upcoming Cancer Pipeline
  4. MD Anderson and Daiichi Sankyo Enter Research Collaboration to Accelerate Development of Acute Myeloid Leukemia Therapies
  5. Bristol-Myers Squibb and Daiichi Sankyo Announce Research Collaboration to Evaluate Opdivo® (nivolumab) and DS-8201 in HER2-Expressing Breast and Bladder Cancers
  6. Daiichi Sankyo Obtains Approval in Japan for Additional Indication and Dosage for Ovisot® for Injection in Diagnosis of Vasospastic Angina – Media & Investors
  7. 第一三共、経皮吸収癌疼痛治療剤 フェンタニルクエン酸塩貼付剤 後発医薬品の商業化に向け協業